Dr. Seymour on the Efficacy Ibrutinib Versus Chemoimmunotherapy in Older Patients With CLL

Video

Erlene Seymour, MD, discusses the use of ibrutinib versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia.

Erlene Seymour, MD, an assistant clinical professor at Wayne State University School of Medicine and a hematologist/oncologist at Barbara Ann Karmanos Cancer Institute, discusses the use of ibrutinib (Imbruvica) versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia (CLL).

Data from a randomized phase 3 trial (NCT01886872) revealed that treatment with ibrutinib led to improved progression-free survival (PFS) versus treatment with bendamustine and rituximab (Rituxan; BR) in older patients with previously untreated CLL.

Additional analyses showed that patients with IGHV-mutated CLL experienced longer PFS versus patients with IGHV-unmutated disease.

The observed safety profile of ibrutinib was as expected and included atrial fibrillation, bleeding, and diarrhea. However, higher rates of hypertension were observed compared with clinical experience, concludes Seymour.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,